Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 59

1.

Efficacy of Vandetanib in Treating Locally Advanced or Metastatic Medullary Thyroid Carcinoma According to RECIST Criteria: A Systematic Review and Meta-Analysis.

Trimboli P, Castellana M, Virili C, Giorgino F, Giovanella L.

Front Endocrinol (Lausanne). 2018 May 3;9:224. doi: 10.3389/fendo.2018.00224. eCollection 2018.

2.

Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.

Abdel-Rahman O, Elsayed Z, Elhalawani H.

Cochrane Database Syst Rev. 2018 Apr 6;4:CD011746. doi: 10.1002/14651858.CD011746.pub2. Review.

PMID:
29624208
3.

Risk of rash associated with vandetanib treatment in non-small-cell lung cancer patients: A meta-analysis of 9 randomized controlled trials.

Liu Y, Qi M, Hou S, Shao L, Zhang J, Li Y, Liu Q.

Medicine (Baltimore). 2017 Oct;96(43):e8345. doi: 10.1097/MD.0000000000008345.

4.

Incidence and risk of cardiotoxicity in cancer patients treated with targeted therapies.

Santoni M, Guerra F, Conti A, Lucarelli A, Rinaldi S, Belvederesi L, Capucci A, Berardi R.

Cancer Treat Rev. 2017 Sep;59:123-131. doi: 10.1016/j.ctrv.2017.07.006. Epub 2017 Jul 28. Review.

PMID:
28818671
5.

Fatigue associated with newly approved vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: an up-to-date meta-analysis.

Li J, Gu J.

Int J Clin Oncol. 2017 Oct;22(5):807-816. doi: 10.1007/s10147-017-1167-1. Epub 2017 Jul 21.

PMID:
28733794
6.
7.

Effectiveness of antiangiogenic drugs in glioblastoma patients: A systematic review and meta-analysis of randomized clinical trials.

Lombardi G, Pambuku A, Bellu L, Farina M, Della Puppa A, Denaro L, Zagonel V.

Crit Rev Oncol Hematol. 2017 Mar;111:94-102. doi: 10.1016/j.critrevonc.2017.01.018. Epub 2017 Jan 30. Review.

PMID:
28259301
8.

Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: A systematic review and meta-analysis.

Abdel-Qadir H, Ethier JL, Lee DS, Thavendiranathan P, Amir E.

Cancer Treat Rev. 2017 Feb;53:120-127. doi: 10.1016/j.ctrv.2016.12.002. Epub 2016 Dec 30. Review.

PMID:
28104567
9.

Kinase Inhibitors in Multitargeted Cancer Therapy.

Gentile C, Martorana A, Lauria A, Bonsignore R.

Curr Med Chem. 2017;24(16):1671-1686. doi: 10.2174/0929867324666170112112734. Review.

PMID:
28078996
10.

Anti-angiogenic Therapy in Patients with Advanced Gastric and Gastroesophageal Junction Cancer: A Systematic Review.

Chen LT, Oh DY, Ryu MH, Yeh KH, Yeo W, Carlesi R, Cheng R, Kim J, Orlando M, Kang YK.

Cancer Res Treat. 2017 Oct;49(4):851-868. doi: 10.4143/crt.2016.176. Epub 2017 Jan 3. Review.

11.

A systematic review and meta-analysis of the risk of diarrhea associated with vandetanib treatment in carcinoma patients.

Huo Z, Yu S, Hong S, Cao X, Xiu L, Liao Z, Li Y, Xiao H.

Onco Targets Ther. 2016 Jun 20;9:3621-31. doi: 10.2147/OTT.S96830. eCollection 2016.

12.

Incidence and risk of hypertension associated with cabozantinib in cancer patients: a systematic review and meta-analysis.

Zhang X, Shao Y, Wang K.

Expert Rev Clin Pharmacol. 2016 Aug;9(8):1109-15. doi: 10.1080/17512433.2016.1190269. Epub 2016 Jun 1. Review.

PMID:
27181268
13.

Consensus on management of advanced medullary thyroid carcinoma on behalf of the Working Group of Thyroid Cancer of the Spanish Society of Endocrinology (SEEN) and the Spanish Task Force Group for Orphan and Infrequent Tumors (GETHI).

Grande E, Santamaría Sandi J, Capdevila J, Navarro González E, Zafón Llopis C, Ramón Y Cajal Asensio T, Gómez Sáez JM, Jiménez-Fonseca P, Riesco-Eizaguirre G, Galofré JC.

Clin Transl Oncol. 2016 Aug;18(8):769-75. doi: 10.1007/s12094-015-1465-x. Epub 2015 Dec 21. Review.

PMID:
26687366
14.

Risk of Gastrointestinal Events During Vandetanib Therapy in Patients With Cancer: A Systematic Review and Meta-analysis of Clinical Trials.

Yang X, Pan X, Cheng X, Kuang Y, Cheng Y.

Am J Ther. 2017 May;24(3):e351-e360. doi: 10.1097/MJT.0000000000000306. Review.

PMID:
26280290
15.

New agent to treat advanced or metastasized thyroid cancer, its efficacy, safety, and mechanism.

Zhu HG, Zhao JY, Zhang R, Liao L, Dong JJ.

Thorac Cancer. 2015 Jul;6(4):539-43. doi: 10.1111/1759-7714.12238. Epub 2015 Feb 17.

16.

Systemic treatment of advanced differentiated and medullary thyroid cancer. Overview and practical aspects.

Kreissl MC, Fassnacht M, Mueller SP.

Nuklearmedizin. 2015;54(3):88-93. Review.

PMID:
26105716
17.

Meta-analysis of the risks of hypertension and QTc prolongation in patients with advanced non-small cell lung cancer who were receiving vandetanib.

Liu Y, Liu Y, Fan ZW, Li J, Xu GG.

Eur J Clin Pharmacol. 2015 May;71(5):541-7. doi: 10.1007/s00228-015-1831-1. Epub 2015 Mar 11.

PMID:
25753291
18.

Consensus on the management of advanced medullary thyroid carcinoma on behalf of the Working Group of Thyroid Cancer of the Spanish Society of Endocrinology (SEEN) and the Spanish Task Force Group for Orphan and Infrequent Tumors (GETHI).

Galofré JC, Santamaría Sandi J, Capdevila J, Navarro González E, Zafón Llopis C, Ramón Y Cajal Asensio T, Gómez Sáez JM, Jiménez-Fonseca P, Riesco Eizaguirre G, Grande E.

Endocrinol Nutr. 2015 Apr;62(4):e37-46. doi: 10.1016/j.endonu.2015.01.005. Epub 2015 Feb 26.

PMID:
25732322
19.

Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors.

Ghatalia P, Morgan CJ, Je Y, Nguyen PL, Trinh QD, Choueiri TK, Sonpavde G.

Crit Rev Oncol Hematol. 2015 May;94(2):228-37. doi: 10.1016/j.critrevonc.2014.12.008. Epub 2014 Dec 19. Review.

PMID:
25577572
20.

Therapy of endocrine disease: response and toxicity of small-molecule tyrosine kinase inhibitors in patients with thyroid carcinoma: a systematic review and meta-analysis.

Klein Hesselink EN, Steenvoorden D, Kapiteijn E, Corssmit EP, van der Horst-Schrivers AN, Lefrandt JD, Links TP, Dekkers OM.

Eur J Endocrinol. 2015 May;172(5):R215-25. doi: 10.1530/EJE-14-0788. Epub 2015 Jan 8. Review.

Supplemental Content

Loading ...
Support Center